Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
The integrated approach is designed to adapt to the evolving needs of new therapeutic modalities, delivering both speed and performance.
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results